Sonablate, intended for use in the focused ablation of prostate tissue, first gained regulatory clearance in October 2015.
The new device contains an updated physical structure and software interface, offering new capabilities to monitor tissue changes and provide altered ultrasound delivery sequences, among other features.
SonaCare expects the new device to decrease overall procedure time by as much as 40 percent, according to a news release.
More articles on supply chain:
6 noteworthy drugs the FDA approved in 2016
HHS Sec. Burwell’s advice to Dr. Tom Price: Prioritize cybersecurity
Valeant to sell off $2B in assets to ease debt: 3 takeaways
